National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$59.95
add to cart

Rights & Permissions

topleft topright

Dietary Supplements: A Framework for Evaluating Safety (2005)
Institute of Medicine (IOM)

Citation Manager

. "11 Applying the Framework: Case Studies Using the Prototype Safety Monographs." Dietary Supplements: A Framework for Evaluating Safety. Washington, DC: The National Academies Press, 2005.

Please select a format:

BibTeX EndNote RefMan


Page
271
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Dietary Supplements: A Framework for Evaluating Safety

the Framework presented in this final report. In the case studies that follow, additional reasons that might have generated a signal for FDA to examine the dietary supplement ingredient are also noted. Using the Framework, FDA would have considered the nature of the evidence readily available as a result of the signal detected and decided, based on initial review, that a level of concern existed. A decision whether to continue monitoring or to move into the integrative evaluation of the dietary supplement ingredient would then have been made.

Integrative Evaluation

An IOM staff monographer developed a search strategy for each ingredient based on recommendations from the committee and began collecting and collating the data available. In order to simulate the initial evaluation in which an internal scientific review would determine which aspects were relevant to include in a comprehensive evaluation, a working group was assembled that included some committee members plus consultants who were chosen based on specific expertise relevant to the dietary supplement ingredient. An initial meeting was held of each prototype working group with the monographer to give direction to the literature search and additional relevant data to be included; at this point, the main activity was to complete the monograph outline.

The working groups reviewed and revised the developing draft monographs as new information was provided and consulted with the monographer via conference calls. Following the procedures outlined in the proposed framework, draft prototype monographs without recommendations or conclusions were released for comment and additional input. Stakeholders were notified of their existence and how to provide comment and feedback.

External Advisory Committee

The role of the working group next changed to become a prototype of an external advisory committee in which participants reviewed and analyzed the data and developed statements regarding concerns about safety. A second meeting was held of each working group in which the group served in the capacity of an external advisory committee. At the second meeting, they received oral comments from stakeholders and reviewed additional information received. They subsequently drafted recommendations and conclusions (see summary analyses, Appendixes D through I).

Page
271
Front Matter (R1-R20)
Executive Summary (1-18)
1 Introduction and Background (19-42)
2 Approaches Used by Others and Existing Safety Frameworks (43-84)
3 The Framework (85-125)
4 Categories of Scientific Evidence--Human Information and Data (126-155)
5 Categories of Scientific Evidence--Animal Data (156-174)
6 Categories of Scientific Evidence--Information About Related Substances (175-216)
7 Categories of Scientific Evidence--In Vitro Data (217-234)
8 Interactions (235-246)
9 Vulnerable Groups and Prevalance of Use (247-252)
10 Scientific Principles for Integrating and Evaluating the Available Data (253-268)
11 Applying the Framework: Case Studies Using the Prototype Safety Monographs (269-291)
12 Factors Influencing Use of the Safety Framework (292-296)
13 Findings and Recommendations (297-306)
Appendix A: Existing Frameworks or Systems for Evaluating the Safety of Other Substances (307-315)
Appendix B: Scope of Work and Comments to Initial July 2002 Framework (316-321)
Appendix C: Plant Family Information (322-355)
Appendix D: Chaparral: Prototype Monograph Summary (356-362)
Appendix E: Glucosamine: Prototype Monograph Summary (363-366)
Appendix F: Melatonin: Prototype Monograph Summary (367-371)
Appendix G: Chromium Picolinate: Prototype Monograph Summary (372-375)
Appendix H: Saw Palmetto: Prototype Monograph Summary (376-379)
Appendix I: Shark Cartilage: Prototype Monograph Summary (380-384)
Appendix J: Prototype Focused Monograph: Review of Liver-Related Risks for Chaparral (385-449)
Appendix K: Protoype Focused Monograph: Review of Anti-Androgenic Risks of Saw Palmetto Ingestion by Women (450-477)
Appendix L: Acknowledgements (478-480)
Appendix M: Biographical Sketches of Commitee Members (481-488)
Index (489-506)